<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58607">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343042</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-017</org_study_id>
    <nct_id>NCT02343042</nct_id>
  </id_info>
  <brief_title>Selinexor and Backbone Treatments of Multiple Myeloma Patients</brief_title>
  <acronym>STOMP</acronym>
  <official_title>A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will independently assess the efficacy and safety of four combination therapies
      for the treatment of patients with relapsed/refractory multiple myeloma (RR MM): selinexor +
      pomalidomide + dexamethasone (SPd), selinexor + bortezomib + dexamethasone (SVd), selinexor
      + lenalidomide+ dexamethasone (SRd), and selinexor + daratumumab + dexamethasone (SDd). The
      abbreviations for combination treatments have been revised to use V (Velcade) for bortezomib
      and R (Revlimid) for lenalidomide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, open-label, randomized (for dose schedule) clinical study with dose escalation
      (Phase 1) and expansion (Phase 2) stages to independently assess the maximum tolerated dose
      (MTD,) efficacy, and safety of selinexor + pomalidomide + dexamethasone (SPd), selinexor +
      bortezomib + dexamethasone (SVd), selinexor + lenalidomide + dexamethasone (SRd), and
      selinexor + daratumumab + dexamethasone (SDd) in patients with relapsed/refractory multiple
      myeloma (RR MM).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerated Dose (MTD) and Recommended Phase 2 dose (RP2D) for Selinexor</measure>
    <time_frame>12 months</time_frame>
    <description>- Determine the MTD and RP2D; selinexor once weekly or twice weekly for all arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events as a measure of safety and tolerability</measure>
    <time_frame>12 months</time_frame>
    <description>- Evaluate the safety and tolerability of SPd (selinexor + pomalidomide + dexamethasone), SVd (selinexor + bortezomib + dexamethasone ), SRd (selinexor + lenalidomide + dexamethasone ), and SDd (selinexor + daratumumab + dexamethasone) in patients with relapsed/refractory multiple myeloma using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v 4.03.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm 1 Selinexor, Low-dose Dexamethasone &amp; Pomalidomide (SPd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomalidomide will be dosed at 4 mg daily for 21 days per cycle.
Cohort 1.1: Selinexor 80 mg with dexamethasone 40 mg once weekly . Cohort 1.2: Selinexor 60 mg with dexamethasone 20 mg twice weekly ; dexamethasone 40 mg weekly will also be given (without selinexor) on Days 22 &amp; 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Selinexor, Low-dose Dexamethasone &amp; Bortezomib (SVd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle is either 21 or 35 days (depending on bortezomib dosing schedule).
Cohort 2.1: Selinexor 80 mg with dexamethasone 40 mg once weekly. Bortezomib 1.3 mg/m2 subcutaneous (SC) once weekly.
Cohort 2.2: Selinexor 60 mg with dexamethasone 20 mg twice weekly; dexamethasone 40 mg weekly will also be given on Days 29 and 31. Bortezomib 1.3 mg/m2 SC dosed once weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 Selinexor, Low-dose dexamethasone, &amp; Lenalidomide (SRd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide at 25mg daily for 21 days per 28 day cycle. Cohort 3.1: Selinexor 80mg with dexamethasone 40mg once weekly. Cohort 3.2: Selinexor 60mg with dexamethasone 20mg twice weekly; dexamethasone 40mg weekly will also be given (without selinexor) on Days 22 and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 Selinexor, Low-dose dexamethasone, &amp; Daratumumab (SDd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab at 16mg/kg IV every week for cycles 1 and 2; then every 2 weeks for cycles 3-6, then once a month for cycles 6 and beyond. A cycle is 28 days.
Cohort 4.1: Selinexor 100mg with dexamethasone 40mg once weekly. Cohort 4.2: Selinexor 60mg with dexamethasone 20mg twice weekly;
dexamethasone 40mg weekly, or equivalent dose of other corticosteroid, may be given intravenously or by mouth will also be given (without selinexor: For once weekly dosing, Cycles 1 and 2: Days 2, 3, 9, 10, 16, 17, 23, and 24; Cycles 3-6: Days 2, 3, 16, and 17; Cycles &gt;6: Days 2 and 3. For twice weekly dosing, Cycles 1 and 2: Days 2, 9, 16, 17, 22, 23, and 24; Cycles 3-6: Days 2, 16, 22, 24; Cycles &gt;6: Days 2, 22, and 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Arm 1 Selinexor, Low-dose Dexamethasone &amp; Pomalidomide (SPd)</arm_group_label>
    <arm_group_label>Arm 2 Selinexor, Low-dose Dexamethasone &amp; Bortezomib (SVd)</arm_group_label>
    <arm_group_label>Arm 3 Selinexor, Low-dose dexamethasone, &amp; Lenalidomide (SRd)</arm_group_label>
    <arm_group_label>Arm 4 Selinexor, Low-dose dexamethasone, &amp; Daratumumab (SDd)</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral tablets in a multi-dose vial.</description>
    <arm_group_label>Arm 1 Selinexor, Low-dose Dexamethasone &amp; Pomalidomide (SPd)</arm_group_label>
    <arm_group_label>Arm 2 Selinexor, Low-dose Dexamethasone &amp; Bortezomib (SVd)</arm_group_label>
    <arm_group_label>Arm 3 Selinexor, Low-dose dexamethasone, &amp; Lenalidomide (SRd)</arm_group_label>
    <arm_group_label>Arm 4 Selinexor, Low-dose dexamethasone, &amp; Daratumumab (SDd)</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25mg Oral capsule</description>
    <arm_group_label>Arm 3 Selinexor, Low-dose dexamethasone, &amp; Lenalidomide (SRd)</arm_group_label>
    <other_name>REVLIMID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>4 mg oral tablets</description>
    <arm_group_label>Arm 1 Selinexor, Low-dose Dexamethasone &amp; Pomalidomide (SPd)</arm_group_label>
    <other_name>Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>3.5mg for injection supplied as lyophilized powder in single-use viles for subcutaneous injection.</description>
    <arm_group_label>Arm 2 Selinexor, Low-dose Dexamethasone &amp; Bortezomib (SVd)</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>16mg/kg Intravenous</description>
    <arm_group_label>Arm 4 Selinexor, Low-dose dexamethasone, &amp; Daratumumab (SDd)</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diagnosis, measurable disease and evidence of disease
             progression of MM, as described below.

          2. Symptomatic MM, based on IMWG guidelines. Patients must have measurable disease as
             defined by at least one of the following:

               -  Serum M-protein ≥ 0.5 g/dL by serum electrophoresis (SPEP) or, for IgA myeloma,
                  by quantitative IgA

               -  Urinary M-protein excretion at least 200 mg/24 hours

               -  Serum FLC ≥ 100 mg/L, provided that FLC ratio is abnormal

               -  If serum protein electrophoresis is felt to be unreliable for routine M-protein
                  measurement, then quantitative Ig levels by nephelometry or turbidometry are
                  acceptable.

          3. Any non-hematological toxicities (except for peripheral neuropathy as described in
             exclusion criterion #22) that patients experienced from treatments in previous
             clinical studies must have resolved to ≤ Grade 2 by Cycle 1 Day 1.

          4. Adequate hepatic function within 21 days prior to C1 D1:

          5. Adequate renal function within 21 days prior to C1 D1:

          6. Adequate hematopoietic function within 21 days prior to C1 D1:

          7. SPd (Arm 1) Only:

             Relapsed and refractory MM with:

               -  Documented evidence of PD after achieving at least SD for ≥ 1 cycle during a
                  previous MM regimen (i.e., relapsed MM)

               -  ≤ 25% response (i.e., patients never achieved ≥ MR) or PD during or within 60
                  days from the end of the most recent MM regimen (i.e., refractory MM)

               -  Previously undergone ≥ 2 cycles of lenalidomide and a proteasome inhibitor (in
                  separate therapeutic regimens [not for maintenance] or in combination)

          8. SVd (Arm 2) Only:

             Relapsed or refractory MM with:

               -  Documented evidence of relapse after ≥ 1 previous line of therapy

               -  Not refractory to bortezomib in their most recent line of therapy

          9. SRd (Arm 3) Only:

               -  Patients who received ≥ 1 prior therapeutic regimen (prior lenalidomide is
                  allowed as long as patient was not refractory to prior lenalidomide)

         10. SDd (Arm 4 Only):

               -  Patients who received ≥ 3 prior lines of therapy, including a proteasome
                  inhibitor and an immunomodulatory agent.

        Exclusion Criteria:

          1. Smoldering MM.

          2. MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded), and
             quantitative immunoglobulin levels cannot be used instead

          3. Documented active systemic amyloid light chain amyloidosis

          4. Active MM involving the central nervous system (CNS)

          5. Active plasma cell leukemia

          6. Blood (or blood product) transfusions and blood growth factors within 7 days of C1 D1
             only for patients enrolling into the Expansion Phase

          7. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks
             prior to C1 D1, and radio-immunotherapy within 6 weeks prior to C1 D1. Patients on
             long-term glucocorticoids during Screening, including use for spinal cord
             compression, do not require a washout period. Prior radiation is permitted for
             treatment of fractures or to prevent fractures as well as for pain management

          8. Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1 D1

          9. Prior autologous stem cell transplantation &lt; 1 month, or allogeneic stem cell
             transplantation &lt; 3 months prior to C1 D1

         10. Active graft versus host disease after allogeneic stem cell transplantation

         11. A life expectancy of &lt; 3 months

         12. Major surgery within 4 weeks prior to C1 D1

         13. Active, unstable cardiovascular function:

               1. Symptomatic ischemia, or

               2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients
                  with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st
                  degree atrioventricular (AV) block or asymptomatic left anterior fascicular
                  block/right bundle branch block (LAFB/RBBB) will not be excluded), or

               3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3,
                  or

               4. Myocardial infarction (MI) within 3 months prior to C1 D1

               5. Ejection fraction (EF) &lt; 50% at screening

         14. Uncontrolled active hypertension

         15. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or
             antifungals within one week prior to first dose

         16. Known active hepatitis A, B or C

         17. Known HIV infection or HIV seropositivity

         18. Prior history of malignancies: cancer treated with curative intent &gt; 5 years before
             study enrollment and without evidence of recurrence will be allowed. Cancer treated
             with curative intent &lt; 5 years previously will not be allowed unless approved by the
             medical monitor. Exceptions include:

               1. Resected basal or squamous cell carcinoma of the skin

               2. Carcinoma in situ of the cervix

         19. Any active gastrointestinal dysfunction that prevents the patient from swallowing
             tablets, or interferes with absorption of study treatment

         20. Currently pregnant or breastfeeding

         21. A serious psychiatric or medical condition which, in the opinion of the investigator,
             could interfere with treatment

         22. Hypersensitivity to any of the treatments for the Arm in which the patient is
             enrolled

         23. In the SVd (Arm 2)only:

             -Prior history of neuropathy Grade &gt; 2, or Grade 2 neuropathy with pain at screening
             (within 21 days prior to C1 D1)

         24. Prior participation in a selinexor clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <email>mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>SShacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jonnsson Comprehensive Cancer Center / University of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>0095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Schiller, MD, PhD</last_name>
      <phone>888-798-0719</phone>
      <email>GSchiller@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Lentzsch, MD</last_name>
      <phone>212-305-5065</phone>
      <email>CTOInformation@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Lentzsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Institute of Cancer/ Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gasparetto, MD</last_name>
      <phone>919-668-1017</phone>
      <email>gaspa001@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Cristina Gasparetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Bensinger, MD</last_name>
      <phone>855-922-6237</phone>
    </contact>
    <investigator>
      <last_name>William Bensinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Alberta Cancer Research Institute / University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazar Bahlis</last_name>
      <phone>+1 (403) 944-1880</phone>
      <email>nbahlis@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute / University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Venner</last_name>
      <phone>780-432-8771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver,</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Haqq</last_name>
      <phone>604.736.2033</phone>
    </contact>
    <investigator>
      <last_name>Heather Sutherland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Newfoundland</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Bergstrom</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darrell White</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre / Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saima Dean</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>5241</phone_ext>
    </contact>
    <investigator>
      <last_name>Christine Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital / McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>L'Hôtel-Dieu de Québec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Agency - Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7TI</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haji Chalchal</last_name>
      <phone>639-625-2010</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>January 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selinexor</keyword>
  <keyword>KCP-330</keyword>
  <keyword>STOMP</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed/Refractory</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Daratumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
